M0173
Myelodysplastic Syndrome (MDS) panel
Number of Tests | 4 |
Test Included | CALR, JAK Exon 12, JAK V617F, MPL Exon 10 |
Test Details: Myelodysplastic syndromes (MDSs) are heterogeneous hematopoietic disorders associated with various degrees of myelosuppression and transformation into acute leukemia. 5q deletion in MDS is considered as a favourable prognosis. Complete loss of chromosome 7 (monosomy 7) or partial deletion involving its long arm [del(7q)] are highly recurrent chromosomal aberrations in myeloid disorders, including myelodysplastic syndrome (MDS). Fluorescence in situ hybridization (FISH) complements conventional karyotyping by the ability to evaluate large numbers of both interphase and metaphase nuclei. This has an important diagnostic and prognostic role which affects the choice of therapies.
![](assets/img/diagnleftimg.png)
Category
Cytogenetics
Pre-test Information
Clinical history, CBC report and treatment status of the patient is mandatory.
Report Delivery
4 working days
Gender
All
Organ
Blood / Bone Marrow
Myelodysplastic Syndrome (MDS) panel
8500
Most Searched Diagnostic Tests